Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria
The DOI matches its Crossref record; 88 of the 88 references it cites were found in a registry or an index.
Abstract
The complement system provides critical immunoprotective and immunoregulatory functions but uncontrolled complement activation can lead to severe pathology. In the rare hemolytic disease paroxysmal nocturnal hemoglobinuria (PNH), somatic mutations result in a deficiency of glycosylphosphatidylinositol-linked surface proteins, including the terminal complement inhibitor CD59, on hematopoietic stem cells. In a dysfunctional bone marrow background, these mutated progenitor blood cells expand and populate the periphery. Deficiency of CD59 on PNH red blood cells results in chronic complement-mediated intravascular hemolysis, a process central to the morbidity and mortality of PNH. A recently developed, humanized monoclonal antibody directed against complement component C5, eculizumab (Soliris; Alexion Pharmaceuticals Inc., Cheshire, CT, USA), blocks the proinflammatory and cytolytic effects of terminal complement activation. The recent approval of eculizumab as a first-in-class complement inhibitor for the treatment of PNH validates the concept of complement inhibition as an effective therapy and provides rationale for investigation of other indications in which complement plays a role.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Eculizumab exemplifies a more extreme case. It binds human complement component C5 with high affinity but does not cross-react with rodent C5. Conventional rodent PK and pharmacology studies are therefore essentially uninformative regarding target engagement.”
From Beyond Body Weight: A Comprehensive Review of Allometric Scaling in Drug Development for Human Dose Predictions (2026) · cites this paper as [53]
Citations
Cites
1 retracted
The structure of complement C3b provides insights into complement activation and regulation
Ajees, A. A., Gunasekaran, K., Volanakis, J. E., Narayana, S. V. L., Kotwal, G. J., & Murthy, H. M. K. (2006) · Nature · doi:10.1038/nature05258 · Cited by 70
RetractedHematology: Basic Principles and Practice
(1991) · Annals of Internal Medicine · doi:10.7326/0003-4819-115-3-238_2 · Cited by 1,857
Reshaping human antibodies for therapy
Riechmann, L., Clark, M., Waldmann, H., & Winter, G. (1988) · Nature · doi:10.1038/332323a0 · Cited by 1,562
Rother, R. P., Bell, L., Hillmen, P., & Gladwin, M. T. (2005) · JAMA · doi:10.1001/jama.293.13.1653 · Cited by 1,557
Walport, M. J. (2001) · New England Journal of Medicine · doi:10.1056/nejm200104123441506 · Cited by 1,481
ENDOGENOUS NITRIC OXIDE INHIBITS HUMAN PLATELET ADHESION TO VASCULAR ENDOTHELIUM
Radomski, M. W., Palmer, R. M. J., & Moncada, S. (1987) · The Lancet · doi:10.1016/s0140-6736(87)91481-4 · Cited by 1,437
The Complement Inhibitor Eculizumab in Paroxysmal Nocturnal Hemoglobinuria
Hillmen, P., Young, N. S., Schubert, J., Brodsky, R. A., Socié, G., Muus, P., Röth, A., Szer, J., Elebute, M. O., Nakamura, R., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa061648 · Cited by 1,303
Radomski, M. W., Palmer, R. M. J., & Moncada, S. (1987) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.1987.tb11367.x · Cited by 1,164
Takeda, J., Miyata, T., Kawagoe, K., Iida, Y., Endo, Y., Fujita, T., Takahashi, M., Kitani, T., & Kinoshita, T. (1993) · Cell · doi:10.1016/0092-8674(93)90250-t · Cited by 1,029
Generation of C5a in the absence of C3: a new complement activation pathway
Huber-Lang, M., Sarma, J. V., Zetoune, F. S., Rittirsch, D., Neff, T. A., McGuire, S. R., Lambris, J. D., Warner, R. L., Flierl, M. A., Hoesel, L. M., et al. (2006) · Nature Medicine · doi:10.1038/nm1419 · Cited by 975
Research works printed but not linked: 4
- Male, D., Brostoff, J., Roth, D. & Roitt, I. Immunology (Mosby-Elsevier, Philadelphia, 2006).
- Jain, R.I., Moreland, L.W., Caldwell, J.R., Rollins, S.A. & Mojcik, C.F. A single dose, placebo controlled, double blind, phase I study of the humanized anti-C5 antibody h5G1.1 in patients with rheumatoid arthritis. Arthritis Rheum. 42, S77 (1999).
- Tesser, J. et al. Safety and efficacy of the humanized anti-C5 antibody h5G1.1 in patients with rheumatoid arthritis. Arthritis Rheum. 44, S274 (2001).
- Rotoli, B. & Luzzatto, L. Paroxysmal nocturnal hemoglobinuria. Semin. Hematol. 26, 201–207 (1989).
Cited by
Items 701–780 of 780
Future Strategies of Complement Inhibition in Paroxysmal Nocturnal Hemoglobinuria
Risitano, A. M. (2017) · Springer eBooks · doi:10.1007/978-4-431-56003-6_20
Epidemiology in PNH: The PNH Global Registry
Brodsky, R. A. (2017) · Springer eBooks · doi:10.1007/978-4-431-56003-6_5
Rare Bone Marrow Failure Conditions
Duffield, A. S., & Dezern, A. E. (2017) · Wiley eBooks · doi:10.1002/9781119196235.ch54
Complement-mediated microglial priming : an in vitro study
Wheat, R. (2016) · ORCA Online Research @Cardiff (Cardiff University)
Analytical validation of an alternative method to quantify specific antibodies in 3 applications
Sénant, M., Bordereau, P., Tartour, É., & Dragon‐Durey, M. (2018) · Journal of Immunological Methods · doi:10.1016/j.jim.2018.10.008
Analytical comparison of Soliris® and its biosimilar, PRK-001
Жученко, М. А., Orlova, N. V., Zybin, D., Nikolaeva, V. V., Klishin, A. A., Lobanova, N. V., Soldatov, V. O., Romanova, N. A., & Seregin, Y. A. (2020) · Biotekhnologiya · doi:10.21519/0234-2758-2020-36-1-73-86
From functions to mechanisms of the prototypic complement C5 antibody BB5.1
Milling, S. W. F. (2020) · Immunology · doi:10.1111/imm.13261
Thrombopenie und Thrombosen bei einer jungen Frau
Tatsis, S., Malkowski, L., & Güldenzoph, B. (2020) · Zeitschrift für Rheumatologie · doi:10.1007/s00393-020-00896-y
The allosteric modulation of Complement C5 by knob domain peptidesPreprint
Macpherson, A., Laabei, M., Ahdash, Z., Graewert, M. A., Birtley, J. R., Schulze, S., Crennell, S. J., Robinson, S. A., Holmes, B., Oleinikovas, V., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.10.24.353714
Is Allogeneic Stem Cell Transplantation a Good Option for Paroxysmal Nocturnal Haemoglobinuria?
Karadağ, F. K., Saydam, G., & Şahin, F. (2020) · EMJ Hematology · doi:10.33590/emjhematol/20-00023
Complementing Subarachnoid Hemorrhage
van Dijk, B. J. (2020) · Utrecht University Repository (Utrecht University) · doi:10.33540/210
Molecular principles of enhanced complement activation by properdin
van den Bos, R. M. (2021) · Utrecht University Repository (Utrecht University) · doi:10.33540/682
Recurrent Disease Challenges in Pediatric Kidney Transplantation
Harshman, L. A., & Bartosh, S. M. (2021) · Springer eBooks · doi:10.1007/978-3-030-74783-1_8
Duran, M. N., Beyazıt, F., Erbaş, M., Özkavak, O. O., Acar, C., & Bakırdöğen, S. (2021) · Obstetric Medicine · doi:10.1177/1753495x211019902
“humanised monoclonal antibody that inhibits the production of the terminal complement components and membrane attack complex C5b-9 by binding to complement C5; it is primarily used to treat a number of autoimmune conditions, including paroxysmal nocturnal hemoglobinuria and HUS.(8) In this case report, we describe a p…”
BackgroundInfluentialRenders, L. (2012) · Der Nephrologe · doi:10.1007/s11560-011-0563-1
Hémoglobinurie paroxystique nocturne
Socié, G., de Latour, R. P., & Mary, J. Y. (2010) · Encyclopédie médico-chirurgicale. Hématologie · doi:10.1016/s1155-1984(10)50909-9
Popescu, N. I., & Lupu, F. (2020) · Springer eBooks · doi:10.1007/978-3-030-53606-0_12
10. Complement and Diseases-what Physicians Should Know
Horiuchi, T. (2020) · Nihon Naika Gakkai Zasshi · doi:10.2169/naika.109.1925
Faculty Opinions recommendation of Current progress in innovative engineered antibodies.
Abdiche, Y. N. (2019) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.729268838.793560915
Eculizumab treatment of atypical hemolytic uremic syndrome
Kaplan, B. S., Ruebner, R. L., & Copelovitch, L. A. (2012) · Expert Opinion on Orphan Drugs · doi:10.1080/21678707.2013.750579
Miyamoto, K. (2016) · Springer eBooks · doi:10.1007/978-4-431-55594-0_18
Concurrent acute kidney injury and pancreatitis in a female patient: Answers
Patel, D. B., Farris, A. C., Hanna, C., & Hashim, F. Q. (2022) · Pediatric Nephrology · doi:10.1007/s00467-022-05665-4
Riedl, M., Matsuda‐Abedini, M., Radhakrishnan, S., Hladunewich, M., Lemaire, M. J., Teoh, C. W., Noone, D. G., & Licht, C. P. B. (2022) · Advances in Chronic Kidney Disease · doi:10.1053/j.ackd.2022.04.003 · Cited by 1
Twombley, K. E. (2023) · Springer eBooks · doi:10.1007/978-981-19-6909-6_14
Non-Infectious Post-Transplant Complications: Disease Recurrence and Rejection
Harshman, L. A., Bartosh, S. M., & Marks, S. D. (2023) · Springer eBooks · doi:10.1007/978-3-031-11665-0_68
Santosh, R. (2023) · Biomedical Journal of Scientific & Technical Research · doi:10.26717/bjstr.2023.49.007857
The Benign Clone Causing Aplastic Anaemia
McCann, S. R., & Piccin, A. (2023) · Thalassemia Reports · doi:10.3390/thalassrep13020015
“The morbidity and outcome for PNH has been radically altered by the introduction of the humanised-monoclonal antibody, eculizumab, aimed at component 5 of the complement casca e [21].”
BackgroundGabrili, J. J. M. (2023) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.42.2023.tde-06092023-152250
The complement system in zebrafish tissue regeneration
Keller, L. (2022) · Publication Server of Goethe University Frankfurt am Main (Goethe University Frankfurt) · doi:10.21248/gups.74983
Derême, J., Goodyer, M. J., Baud, D., Alberio, L., Grandoni, F., & Gavillet, M. (2024) · eJHaem · doi:10.1002/jha2.972
Dujmović, I., & Howard, J. F. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-95702-1.00230-x
High‐Sensitivity Detection of Paroxysmal Nocturnal Hemoglobinuria by Multiparameter Flow Cytometry
Al‐Attar, A., Richards, S. J., Marinov, I., Illingworth, A. J., & Sutherland, D. R. (2024) · Wiley eBooks · doi:10.1002/9781683674023.ch15
Updates in atypical hemolytic syndrome
Drake, K. A., & Gattineni, J. (2025) · Current Opinion in Pediatrics · doi:10.1097/mop.0000000000001435
Complement Dysregulation in Infancy: A Case of CD59 Deficiency With Neurological Sequelae
Busaleh, F., Kalaf, H. Y. A., Almajhad, N., Alhalal, R., Alqahtani, J. M., Almuslem, Z., Alqurashi, N. A., Alhejji, M. A., Albeladi, Z. I., & Alessa, S. B. (2025) · Cureus · doi:10.7759/cureus.84085
The Classical Pathway of Complement
Garrigues, R. J., & Garcia, B. L. (2025) · Elsevier eBooks · doi:10.1016/b978-0-12-824465-4.00170-8
Pharmacological characteristics and clinical study results of danicopan (Voydeya® tablets)
Hayashi, H. (2025) · Folia Pharmacologica Japonica · doi:10.1254/fpj.25017
Monoclonal Antibodies Against Human Immunodeficiency Virus (HIV): Current Opinion
Senthilkumar, H., Dhamodharan, P., Eshak, D., Chandrasekaran, S. D., & Arumugam, M. (2025) · Springer eBooks · doi:10.1007/978-3-031-77911-4_4
Manso, T., Sanou, G., Nousias, C., Maalem, I., Boutin, F., Giudicelli, V., Duroux, P., Lefranc, M., & Κοσσίδα, Σ. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.09.03.673706
“This dual attenuation of ADCC and CDC activities significantly reduces the risk of Fc-mediated adverse effects (67).”
Oğuz, S. R., Kıvanç, D., Özdilli, K., Karadeniz, S., Gürer, E. E., & Çiftçi, H. Ş. (2025) · Journal of Kidney Diseases · doi:10.61882/ijkd.19.1.59
Off-label intravitreal eculizumab for geographic atrophy: report of the first two cases
Jorge, R., Rêgo, M. G. B., Zupelli, A. S., & Calado, R. T. (2026) · International Journal of Retina and Vitreous · doi:10.1186/s40942-026-00842-1
Fisiopatologia diagnóstico e novas terapêuticas da hemoglobinúria paroxística noturna
Rodrigues, B. (2011) · Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT) · doi:10.34626/d3ym-zt07
Bi-functional C5 antibody-CR1 fusion for complement inhibitionPreprint
Gong, Y., Chai, X., Jinsong, J., wang, H., Guo, R., Yang, H., Liu, Y., Ma, H., Liu, H., He, G., et al. (2023) · Research Square · doi:10.21203/rs.3.rs-2763376/v1
Therapeutic mechanisms and clinical impact of monoclonal antibodies in myasthenia gravis treatment
AL-Smadi, K., Sodsri, K., Chowdhury, M. A., & Mohammed, Y. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-36647-5.00011-x
FcRn inhibitors: A new era in neurotherapeutics
Howard, J. F., & Guptill, J. T. (2026) · Handbook of clinical neurology · doi:10.1016/b978-0-323-90887-0.00002-x
Cowan, H., Dave, R., Arjunan, A., Maarouf, M., Dean, G., Graciaa, S. H., Schoettler, M. L., & Chonat, S. (2026) · Expert Review of Hematology · doi:10.1080/17474086.2026.2634277
“The downstream effects of C5 inhibition, including decreased generation of proinflammatory mediator C5a, directly correlate to the clinical benefits of eculizumab [25].”
Magdelaine–Beuzelin, C. (2010) · theses.fr (ABES) · doi:10.70675/1eecbe7cz9002z472ez9df3zedc2100ebcb5
Défense et régénération pulpo-dentinaire : activation locale du complément
Rufas, P. (2016) · theses.fr (ABES) · doi:10.70675/aabb9993zfc69z4c52za0e3z15f38b798ff1
Sanabria‐Castro, A., Reyes, J. D. V., Madrigal‐Gamboa, V., & Chin-Cheng, R. (2026) · Neuroglia · doi:10.3390/neuroglia7020012
Grabowski, E. F., Stahl, G. L., Morrissey, M., Mazzotta, C., Rosales, I. A., Ozaki, M., Skjoedt, M., Binrouf, R. H., Davies, J., & Ingelfinger, J. R. (2026) · Pediatric Research · doi:10.1038/s41390-025-04535-7
Woodard, G. E. (2026) · Neurochemistry International · doi:10.1016/j.neuint.2026.106161 · Cited by 1
Zybin, D., Клишин, А. А., Orlova, N. V., Sorokina, T. S., & Kapustin, D. V. (2026) · Fine Chemical Technologies · doi:10.32362/2410-6593-2026-21-2-165-178
Sequence-dominant protein therapeutics: mechanistic foundations for efficient biologics development
Niazi, S. K. (2026) · Frontiers in Drug Discovery · doi:10.3389/fddsv.2026.1781560
Gong, X., Zhu, H., Liu, Z. F., Le, J., Zhao, J., Wan, Y., Li, M., Li, J., Chen, S., Wang, B., et al. (2026) · European journal of medical research · doi:10.1186/s40001-026-04731-z · Cited by 1
“…including both C5a generation and MAC formation—has demonstrated clinical efficacy in complement-mediated diseases such as paroxysmal nocturnal hemoglobinuria (PNH) [120] and generalized myasthenia gravis [121], and has also been explored in transplantation-related complement activation [122].”
Treatment of Myasthenia Gravis
Kaminski, H. J. (2026) · Current clinical neurology · doi:10.1007/978-3-032-19140-3_11
Complement Inhibition in the Clinic: Are We Doing Enough to Protect Patients From Infection?
Bettoni, S., Qviberg, E., Chaloner, E., Lavender, H., & Laabei, M. (2026) · European Journal of Immunology · doi:10.1002/eji.70233
“…monoclonal IgG2/4 κ antibody eculizumab was the first complement therapeutic introduced into clinical practice, approved for treatment of PNH [ 27 ], validating the complement system as a pharmacological target and promoting the development of several other C5 inhibitors for clinical use…”
Zhou, Z., Zhang, C., Jiang, Y., Yuejin, Y., Chen, G., Pan, Q., & Chen, J. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1866207
“Only a few complement inhibitors have been approved by the U.S. Food and Drug Administration (FDA) for clinical use, including C1-inhibitor (Rother et al., 2007).”
Yang, T., Chu, T., Song, X., Wang, Y., Wang, Y., Mao, N., Che, K., Dong, F., Liu, W., Li, A., et al. (2026) · BMC Medical Imaging · doi:10.1186/s12880-026-02602-x
D’Alvano, G., Giudice, S., D’Anna, F., Todisco, V., Tessitore, A., & Bisecco, A. (2026) · NeuroSci · doi:10.3390/neurosci7040085
Cooke, R. S., Lee, K. Y., Menzies, G. E., Mizuno, M., Morgan, B. P., & Zelek, W. M. (2026) · Immunology · doi:10.1111/imm.70180
“Eculizumab/ravulizumab bind the MG7 domain in C5α chain [7, 25, 26]; the epitope includes R885 and the variant R885H (~3% frequency in Japan) confers eculizumab/ravulizumab resistance [11, 27].”
Wang, C., Jiang, L., Li, C.-Y., Tan, Y., Liu, X.-Y., & Liu, L. (2026) · Kidney International Case Reports · doi:10.1016/j.kintcr.2026.100056
Erdemci-Evin, S., Kaupper, V., Sichau, J., Dopler, E., Ghaboosh, H., Dopler, A., & Schmidt, C. Q. (2026) · Immunobiology · doi:10.1016/j.imbio.2026.153233
Lefranc, M. (2026) · Biomolecules · doi:10.3390/biom16091264
“The chimerisotype variant (ID 228) 6-G2v94, G2[11aaG4] [179] (Table S1) characterizes six INN, eculizumab 8231, samalizumab 9307, olendalizumab 10037, ravulizumab 10659, omoprubart 12638 and ascuprubart 13837 (Table S2).”
Jung, M., Ring, M. E., Bonilla, B. G., Ganesan, S., Leon, P. C. V., & Calvo, E. (2026) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2026.113529
Biological (Monoclonal Antibody) Therapies Affecting Red Blood Cells
Anani, W. Q., & Denomme, G. A. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-22427-0.00016-0
Ning, J. Y., Wang, B., Yamamoto, M. I., & Yamada, K. H. (2026) · Cells · doi:10.3390/cells15191772
“In contrast, agents targeting C5, such as tesidolumab (Novartis) [314] and eculizumab (Alexion Pharmaceuticals, Boston, MA, USA) [315–317], agents targeting factor D, such as lampalizumab (Genentech) [318] and danicopan (Alexion Pharmaceuticals) [319], agents targeting factor B, such as iptacopan…”
Congenital/Inherited CD59 Deficiency: A Systematic Review
Alwahiby, L., Alsuhim, L., ALZAHRANI, M., Albaloshi, J., Skrypnyk, C., & Sridharan, K. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15197751
The Expanding Therapeutic Landscape in Myasthenia Gravis
Rashed, H. R. (2026) · Muscle & Nerve · doi:10.1002/mus.70418
BindingDB Entry 50002722: Chemical Approaches to Modulating Complement-Mediated Diseases.
BindingDB (2020) · UC San Diego · doi:10.7270/q2mk6gj9
BindingDB (2012) · UC San Diego · doi:10.7270/q2jm2bhd
Metadata
- Authors
- Rother, R. P., Rollins, S. A., Mojcik, C. F., Brodsky, R. A., & Bell, L.
- Affiliations
- Alexion Pharmaceuticals (United States) (US)
- Johns Hopkins University (US)
- Corresponding author
- Rother, Russell P
- Venue
- Nature Biotechnology
- Published
- 2007-11
- Volume
- 25
- Issue
- 11
- Pages
- 1256-1264
- ISSN
- 0733-222X (ISSN-L)
- 1087-0156
- 1546-1696
- OpenAlex
- W2004265876
- Cited by
- 778
- References
- 88
- Citations by year
- 2026: 34 · 2025: 38 · 2024: 43 · 2023: 58 · 2022: 34 · 2021: 47 · 2020: 59 · 2019: 49 · 2018: 42 · 2017: 52 · 2016: 60 · 2015: 39 · 2014: 41 · 2013: 38 · 2012: 43
- FWCI
- 8.68
- Type
- journal article
- Language
- en
- Update notices
- erratum (2007-12-01)
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Nature Biotechnology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Complement system in diseases
- Health Sciences › Medicine › Hematology › Hemophilia Treatment and Research
- Health Sciences › Medicine › Hematology › Coagulation, Bradykinin, Polyphosphates, and Angioedema
- Keywords
- eculizumab, paroxysmal nocturnal hemoglobinuria, complement inhibition, complement component C5, CD59, intravascular hemolysis, monoclonal antibodies, glycosylphosphatidylinositol deficiency, terminal complement activation, drug development
- MeSH terms
- Animals, Antibodies, Monoclonal, Clinical Trials as Topic, Complement C5, Drug Evaluation, Preclinical, Hemoglobinuria, Paroxysmal, Humans, Drug Design, Protein Engineering, Drug Approval, Complement Inactivating Agents, Mice, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.